US 11,685,722 B2
Inhibition of Olig2 activity
Graham Beaton, San Diego, CA (US); Stanton F. McHardy, Waring, TX (US); Ambrosio Lopez, Jr., San Antonio, TX (US); Bismarck Campos, San Antonio, TX (US); and Hua-Yu Leo Wang, San Antonio, TX (US)
Assigned to CURTANA PHARMACEUTICALS, INC., Austin, TX (US)
Appl. No. 16/976,147
Filed by Curtana Pharmaceuticals, Inc., Austin, TX (US)
PCT Filed Feb. 28, 2019, PCT No. PCT/US2019/020016
§ 371(c)(1), (2) Date Aug. 27, 2020,
PCT Pub. No. WO2019/169112, PCT Pub. Date Sep. 6, 2019.
Claims priority of provisional application 62/636,755, filed on Feb. 28, 2018.
Prior Publication US 2020/0407329 A1, Dec. 31, 2020
Int. Cl. C07D 239/24 (2006.01); C07D 239/28 (2006.01); C07D 239/48 (2006.01); A61K 31/17 (2006.01); A61K 31/495 (2006.01); A61K 31/505 (2006.01); A61P 35/00 (2006.01); C07D 401/12 (2006.01)
CPC C07D 239/48 (2013.01) [A61P 35/00 (2018.01); C07D 401/12 (2013.01)] 14 Claims
 
1. A compound having the structure of Formula (I):

OG Complex Work Unit Chemistry
wherein:

OG Complex Work Unit Chemistry
 is

OG Complex Work Unit Chemistry
 wherein

OG Complex Work Unit Chemistry
 is unsubstituted or substituted by 1, 2 or 3 R1 groups;
each R1 is independently halogen, —CN, —NO2, —OH, —OCF3, —OCH2F, —OCF2H, —CF3, —SR8, —N(R8)S(═O)2R9, —S(═O)2N(R8)2, —S(═O)2R9, —S(═O)2R9, —C(═O)R9, —CO2R8, —N(R8)2, —C(═O)N(R8)2, or —N(R8)C(═O)R9;
R2 and R3 are each independently H, or C1-C4alkyl;
R4 and R5 are independently H, halogen, —CN, —OH, —CF3, or;
R6 is H, unsubstituted C1-C6 haloalkyl,
(C(R14)(R15))mN(R11)(R12), —(C(R14)(R15))mOR13, or —OR22;
each R8 is independently H or C1-C6alkyl;
each R9 is independently C1-C6alkyl;
R10 is H or C1-C4alkyl;
R11 is H, or C1-C6alkyl;
R12 is H or C1-C6 alkyl;
R13 is H or C1-C6alkyl;
each R14 and R15 is each independently H, halogen, or C1-C6alkyl;
R22 is H, or C1-C6alkyl;
m is 2-6; and
n is 1-5; or
a pharmaceutically acceptable salt thereof.